Cargando…
Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
OBJECTIVE: To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. METHODS: Patients with an HCC diagnosis and one or more sorafenib...
Autores principales: | Clouth, Johannes, Liepa, Astra M., Moeser, Guido, Friedel, Heiko, Bernzen, Magdalena, Trojan, Jörg, Garal-Pantaler, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111015/ https://www.ncbi.nlm.nih.gov/pubmed/30151607 http://dx.doi.org/10.1186/s13561-018-0199-1 |
Ejemplares similares
-
Analysis of second opinion programs provided by German statutory and private health insurance – a survey of statutory and private health insurers
por: Könsgen, Nadja, et al.
Publicado: (2021) -
Continuous Case Management of a German Statutory Health Insurance
por: Hecke, Torsten L., et al.
Publicado: (2005) -
Seroconversion after needlestick injuries – analyses of statutory accident insurance claims in Germany
por: Dulon, Madeleine, et al.
Publicado: (2018) -
Promoting vaccinations - an analysis of measures taken by German statutory health insurers
por: Damm, Kathrin, et al.
Publicado: (2011) -
Burden of HPV related anogenital diseases in young women in Germany – an analysis of German statutory health insurance claims data from 2012 to 2017
por: Reuschenbach, Miriam, et al.
Publicado: (2020)